Key clinical point: Half of the patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) who did not respond to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) at 12 weeks were indeed late responders, suggesting the need for extension of treatment duration beyond 12 months.
Major finding: At 12 weeks, 34.4% were nonresponders, of which 55.1% showed response between 13 and 24 weeks and were classified as late responders. Compared with responders, late responders had a higher body mass index (P = .024), more frequent prior treatment failures (P = .017), and psychiatric comorbidities (P = .041).
Study details: This was a prospective, real-life study including 771 patients with HFEM or CM who received anti-CGRP mAb for ≥24 weeks.
Disclosures: This study was partially supported by the Italian Ministry of Health, IRCCS San Raffaele Roma, and Fondazione Italiana Cefalee. Some authors declared receiving travel grants or honoraria for advisory board participations or serving on speaker panels or clinical investigation studies for various sources.
Source: Barbanti P et al for the Italian Migraine Registry study group. Late response to anti-CGRP monoclonal antibodies in migraine: A multicenter, prospective, observational study. Neurology. 2023 (Apr 18). doi: 10.1212/WNL.0000000000207292